Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Anti-CD20-mediated B-cell depletion effectively reduces acute multiple sclerosis (MS) flares. Recent data shows that antibody-mediated extinction of B cells as a lasting immune suppression, harbors the risk of developing humoral deficiencies over time. Accordingly, more selective, durable and reversible B-cell-directed MS therapies are needed. We here tested inhibition of Bruton’s tyrosine kinase (BTK), an enzyme centrally involved in B-cell receptor signaling, as the most promising approach in this direction. Using mouse models of MS, we determined that evobrutinib, the first BTK inhibiting molecule being developed, dose-dependently inhibited antigen-triggered activation and maturation of B cells as well as their release of pro-inflammatory cytokines. Most importantly, evobrutinib treatment functionally impaired the capacity of B cells to act as antigen-presenting cells for the development of encephalitogenic T cells, resulting in a significantly reduced disease severity in mice. In contrast to anti-CD20, BTK inhibition silenced this key property of B cells in MS without impairing their frequency or functional integrity. In conjunction with a recent phase II trial reporting that evobrutinib is safe and effective in MS, our mechanistic data highlight therapeutic BTK inhibition as a landmark towards selectively interfering with MS-driving B-cell properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Costello, F., Stüve, O., Weber, M. S., Zamvil, S. S., & Frohman, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328122de1b · Cited by 46
Self-citation
Cited by
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00237-4 · Cited by 204
Microglia in multiple sclerosis: protectors turn destroyers
Yong, V. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.023 · Cited by 185
Bruton’s tyrosine kinase inhibition in multiple sclerosis
Schneider, R., & Oh, J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01229-z · Cited by 47
Metadata
- Authors
- Torke, S., Pretzsch, R., Häusler, D., Haselmayer, P., Grenningloh, R., Boschert, U., Brück, W., & Weber, M. S.
- Venue
- Acta Neuropathologica
- Published
- 2020-08-06
- Volume
- 140
- Issue
- 4
- Pages
- 535-548
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W3047313223
- Cited by
- 101
- References
- 3
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. https://app.cochat.ai/papers/10.1007/s00401-020-02204-z
- The paper
- Torke, S., Pretzsch, R., Häusler, D., Haselmayer, P., Grenningloh, R., Boschert, U., Brück, W., & Weber, M. S. (2020). Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-020-02204-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.